This study consists of a 4-week screening period, 12-week treatment period, and a 4-week follow up period. Participants will be randomized 1:1:1 to Dose Regimen 1, Dose Regimen 2, or Placebo (\~70 participants/arm).
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18-75 years
Body mass index (BMI) within the range 18 to 40 kg/m2
Diagnosed with PsA for ≥6 months, and meeting Classification Criteria for Psoriatic Arthritis (CASPAR) at screening
Have active PsA: ≥3 tender joints and ≥3 swollen joints at screening and baseline and having hsCRP \>0.3 mg/dL (3 mg/L)
Having active plaque psoriasis (≥1 lesion ≥2cm) or nail psoriasis at screening
Biologic disease modifying anti-rheumatic drug (bDMARD) or targeted synthetic DMARD (tsDMARD) experienced participants can have received (a) up to one bDMARD (excluding TNF and IL-17 targeting therapies), and (b) up to one tsDMARD (excluding JAK targeting therapies)
bDMARD or tsDMARD naïve participants must have failed (a) at least one but no more than two csDMARDs AND/OR (b) Apremilast
You may not be if
Presence of other inflammatory or autoimmune conditions, including but not limited to rheumatoid arthritis, primary ankylosing spondylitis or non-radiographic axial spondyloarthritis without psoriasis, systemic lupus erythematosus, drug-induced dermatosis, inflammatory bowel disease, or Lyme disease
Current non-plaque forms of psoriasis (e.g., erythrodermic, guttate, or pustular psoriasis)
Use of \>10mg/day prednisone equivalent or change in oral glucocorticoid dosage within 4 weeks prior to Baseline
Received targeted intra-articular, trigger point, tender point, intra-bursa, or intra-tendon sheath surgical or pharmacological treatment within 8 weeks of the Screening Visit
Undergone surgical treatment for PsA including synovectomy and arthroplasty in more than 3 joints and/or within the last 12 weeks prior to the Screening Visit.
